Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-16468 |
Brand: | MCE |
CAS: | 148717-90-2 |
MDL | - |
---|---|
Molecular Weight | 627.96 |
Molecular Formula | C34H65N3O5S |
SMILES | C[C@@]12[C@](C[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@@H](CC[C@H](C(C)C)OS(=O)(O)=O)C)([H])C[C@@H](NCCCNCCCCN)CC1 |
Squalamine(MSI-1256) is an aminosterol compound with potent broad spectrum antiviral activity. IC50 value: Target: in vitro: squalamine can strongly displace membrane-bound cationic proteins such as Rac1, a ρ-GTPase recruited to the inner leaflet of the eukaryotic cytoplasmic membrane for the actin remodeling necessary for endocytosis. At concentrations between 20 and 60 μg/mL, squalamine has been shown to inhibit a broad array of growth factor-induced, actin-dependent responses in endothelial cells, including cell migration, cell division, and vascular tube formation in a 3D matrix [1]. Squalamine effectively inhibited HBV replication in human primary hepatocytes when added either during the initial exposure of virus to the cells or at 24 h after infection . A similar study was performed to evaluate the effect of squalamine on the replication of HDV. Squalamine was introduced at 20 μg/mL during HDV exposure, and the effects were measured at day 7 when total RNA was extracted and assayed for HDV RNA sequences [1]. in vivo: one time daily treatment with squalamine (15 or 30 mg/kg per d s.c.) was started beginning on day 1 or 2 after viral administration and continuing until day 8 or 9, respectively. Survival was monitored, and animals that remained alive by day 21 were considered cured [1].
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00139282 | Genaera Corporation |
Wet Age-Related Macular Degeneration
|
June 2005 | Phase 3 |
NCT02614937 | Ohr Pharmaceutical Inc.|Cumberland Valley Retina Consultants, PC |
Retinal Vein Occlusion|Macular Edema
|
April 2013 | Phase 1|Phase 2 |
NCT00333476 | Genaera Corporation |
Macular Degeneration
|
May 2006 | Phase 2 |
NCT00089830 | Genaera Corporation |
Macular Degeneration
|
August 2004 | Phase 2 |
NCT02349516 | Starr Muscle|Ohr Pharmaceutical Inc.|Prism Vision Group |
Diabetic Retinopathy
|
February 2015 | Phase 2 |
NCT01678963 | Ohr Pharmaceutical Inc. |
Neovascular Age Related Macular Degeneration
|
November 2012 | Phase 2 |
NCT00244920 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Prostate Cancer
|
January 2002 | Phase 2 |
NCT01769183 | Elman Retina Group |
Retinal Neovascularization
|
February 2013 | Phase 2 |
NCT00094120 | Genaera Corporation |
Macular Degeneration
|
October 2004 | Phase 2 |
NCT02727881 | Ohr Pharmaceutical Inc. |
Age-related Macular Degeneration
|
April 12, 2016 | Phase 3 |
NCT00021385 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Ovarian Cancer
|
May 2001 | Phase 2 |
NCT02511613 | Ohr Pharmaceutical Inc. |
Age-Related Macular Degeneration
|
July 2015 | Phase 2 |
Solid
Squalus acanthias
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 159.25 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.5925 mL | 7.9623 mL | 15.9246 mL |
5 mM | 0.3185 mL | 1.5925 mL | 3.1849 mL |
10 mM | 0.1592 mL | 0.7962 mL | 1.5925 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.